Next, we demonstrated that the number of tumor specific CD8+IFN-γ+ T cells is increased and that both tumor prevention and tumor treatment effects could be achieved using a tumor-specific antigen pulsed DC-based vaccine with RPS3 as an adjuvant. The gene discussed is IFNG; the disease is neoplasm.